Pacira BioSciences, Inc. Common Stock (PCRX)
Pacira BioSciences, Inc. is a pharmaceutical company specializing in non-opioid, local analgesic products. It is best known for its flagship product, EXPAREL, a long-lasting local anesthetic used for postoperative pain management. The company focuses on developing and commercializing non-opioid pain control options to reduce reliance on opioids and improve patient recovery outcomes.
Company News
Pacira BioSciences will present research at AMCP Nexus 2025 highlighting the clinical effectiveness and economic benefits of EXPAREL, a non-opioid pain therapy, with multiple studies focusing on pain management in knee and shoulder surgeries.
Pacira BioSciences, Inc. (PCRX) is facing a securities fraud lawsuit related to the validity of its patent for Exparel, its main revenue-generating product. The Schall Law Firm is encouraging PCRX investors to join the class action lawsuit.
Barclays downgraded Pacira Pharmaceuticals stock from Overweight to Equalweight due to concerns over the approval of eVenus, which poses a risk to the sales of Pacira's leading product, Exparel.
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.